Biomerica Inc. announced the appointment of Scott Madel as Chief Commercial Officer, bringing over two decades of cross-functional expertise in healthcare, diagnostics, commercialization, and payer strategy. Mr. Madel previously served as President of Boston Heart Diagnostics, where he led a successful organizational turnaround and significantly boosted revenue. He also held CEO roles at BioHealth Diagnostics and Genova Diagnostics Europe, helping grow Genova to over $100 million in annual revenue.
In his new role, Scott Madel will focus on expanding and accelerating commercialization and revenue growth for inFoods IBS. His responsibilities include developing a robust payer strategy, achieving third-party payer reimbursement, and scaling domestic and global provider engagement and brand recognition. This appointment is a strategic move to address critical commercialization challenges and unlock the full market potential of Biomerica's flagship product.
CEO Zack Irani stated that Scott’s rich commercial experience, knowledge, and deep industry relationships should dramatically increase revenues from inFoods IBS across markets. The company is confident that his strategic insights will drive the domestic launch and future international business. Mr. Madel expressed excitement to champion the growth of inFoods IBS, highlighting its potential to improve the quality of life for millions of patients suffering from chronic GI conditions.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.